Statins for the primary prevention of venous thromboembolism

作者：Zixin Wang, Peng Zhang, Jinhui Tian, Peizhen Zhang, Kehu Yang, Lun Li · 发表于：Cochrane Database of Systematic Reviews · 年份：2024 · DOI：10.1002/14651858.cd014769.pub2 · 被引用次数：5 · 研究领域：Venous Thromboembolism Diagnosis and Management、Lipoproteins and Cardiovascular Health、Blood Coagulation and Thrombosis Mechanisms

BACKGROUND: Venous thromboembolism (VTE) involves the formation of a blood clot in a vein, and includes deep venous thrombosis (DVT) or pulmonary embolism (PE). The annual incidence for VTE varies from 0.75 to 2.69 per 1000 individuals, with about 40 million people worldwide impacted by VTE. Statins, 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors, inhibit cholesterol biosynthesis and display several vascular-protective effects, including antithrombotic properties. However, the potential role of statins in the primary prevention of VTE is still not clear. OBJECTIVES: To evaluate the benefits and risks of statins in preventing venous thromboembolism (VTE) in individuals with no prior history of VTE. SEARCH METHODS: We used standard Cochrane search methods. The search was last updated on 13 March 2023. SELECTION CRITERIA: We included randomized controlled trials (RCTs) comparing statins with any control intervention (including placebo and usual care) in healthy individuals or participants with conditions other than VTE. There were no restrictions on the dose, duration, route, or timing of statins. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were VTE, DVT, and PE. Our secondary outcomes were serious adverse events, adverse events, and mortality. We used the trial sequential analysis (TSA) method to judge whether the evidence was sufficient, and we used the GRADE approach to assess the certainty of the evidence for ...